Correction to: Bizino et al. Cardiovasc Diabetol (2019) 18:55 https://doi.org/10.1186/s12933-019-0857-6
Following publication of the original article [1], the authors reported an error in Fig. 3. The bars in the upper right panel that represent heart rate in placebo treated patients is not correct. The revised Fig. 3 is given here.
LV systolic function. Bar graphs of MRI-derived indices of systolic function. Blue bars indicate baseline measurement and red bars follow-up. In the liraglutide group stroke volume decreased, whereas cardiac index remained unchanged because of the increased heart rate. Bpm beats per minute
The authors wish to apologise for this error.
Reference
Bizino Maurice B, Jazet Ingrid M, Westenberg Jos J M, van Eyk Huub J, Paiman Elisabeth H M, Smit Jan W A, Lamb Hildebrandus J. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18:55. https://doi.org/10.1186/s12933-019-0857-6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Bizino, M.B., Jazet, I.M., Westenberg, J.J.M. et al. Correction to: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol 18, 101 (2019). https://doi.org/10.1186/s12933-019-0905-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12933-019-0905-2